A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs SRT 2104 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 03 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2010 Additional locations identified as reported by ClinicalTrials.gov.